FY2030 EPS Estimates for Disc Medicine Increased by Analyst

Disc Medicine, Inc. (NASDAQ:IRON) – Stock analysts at HC Wainwright raised their FY2030 EPS estimates for shares of Disc Medicine in a note issued to investors on Wednesday, May 6th. HC Wainwright analyst D. Tsao now expects that the company will post earnings of $7.40 per share for the year, up from their previous estimate of $7.12. The consensus estimate for Disc Medicine’s current full-year earnings is ($6.68) per share.

Disc Medicine (NASDAQ:IRON) last posted its earnings results on Tuesday, May 5th. The company reported ($1.65) earnings per share for the quarter, missing the consensus estimate of ($1.62) by ($0.03).

Other equities analysts have also issued research reports about the stock. Truist Financial reduced their target price on shares of Disc Medicine from $114.00 to $83.00 and set a “buy” rating on the stock in a report on Friday, February 27th. UBS Group restated an “overweight” rating on shares of Disc Medicine in a report on Thursday, January 15th. Wall Street Zen raised shares of Disc Medicine from a “strong sell” rating to a “sell” rating in a research note on Saturday, April 25th. Morgan Stanley set a $75.00 price target on shares of Disc Medicine in a research note on Tuesday, February 17th. Finally, Cantor Fitzgerald dropped their price target on shares of Disc Medicine from $153.00 to $125.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 17th. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Disc Medicine has a consensus rating of “Moderate Buy” and an average price target of $104.80.

Disc Medicine Stock Performance

NASDAQ:IRON opened at $68.65 on Thursday. The company has a current ratio of 21.94, a quick ratio of 21.94 and a debt-to-equity ratio of 0.04. The firm has a market capitalization of $2.62 billion, a price-to-earnings ratio of -10.37 and a beta of 0.93. The firm’s fifty day simple moving average is $65.01 and its 200 day simple moving average is $76.09. Disc Medicine has a twelve month low of $40.00 and a twelve month high of $99.50.

Insider Activity

In related news, CFO Jean M. Franchi sold 6,257 shares of Disc Medicine stock in a transaction on Tuesday, April 14th. The shares were sold at an average price of $69.24, for a total transaction of $433,234.68. Following the sale, the chief financial officer owned 64,333 shares of the company’s stock, valued at $4,454,416.92. The trade was a 8.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Pamela Stephenson sold 5,531 shares of Disc Medicine stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $62.86, for a total transaction of $347,678.66. Following the sale, the insider directly owned 80,998 shares in the company, valued at $5,091,534.28. This trade represents a 6.39% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 59,410 shares of company stock worth $3,840,013 over the last three months. 3.64% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Disc Medicine

Hedge funds and other institutional investors have recently modified their holdings of the stock. ANTIPODES PARTNERS Ltd bought a new stake in shares of Disc Medicine in the 4th quarter worth about $33,000. Aster Capital Management DIFC Ltd bought a new stake in shares of Disc Medicine in the 3rd quarter worth about $38,000. KBC Group NV bought a new stake in shares of Disc Medicine in the 4th quarter worth about $80,000. Persistent Asset Partners Ltd bought a new stake in shares of Disc Medicine in the 4th quarter worth about $141,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its position in shares of Disc Medicine by 36.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,834 shares of the company’s stock worth $146,000 after purchasing an additional 490 shares during the last quarter. Institutional investors own 83.70% of the company’s stock.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.